SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.
Veno-venous extracorporeal membrane oxygenation support in covid-19 respiratory distress syndrome: Initial experience
Loforte A.
First
;
2020-01-01
Abstract
SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
mat-publish-ahead-of-print-10.1097.mat.0000000000001198.pdf
Accesso riservato
Dimensione
311.91 kB
Formato
Adobe PDF
|
311.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
